Changeflow GovPing Healthcare & Life Sciences Basement Membrane Regeneration Wound Repair Obs...
Routine Notice Added Final

Basement Membrane Regeneration Wound Repair Observational Study

Favicon for changeflow.com ClinicalTrials.gov Studies
Published
Detected
Email

Summary

This document registers a prospective, multicenter, observational study (NCT07551284) evaluating autologous basement membrane regeneration technology for wound repair in 1,000 patients across multiple hospitals in China. The study will compare 500 patients receiving the cell suspension therapy combined with standard surgical procedures against 500 matched patients receiving standard procedures alone, with primary outcomes including complete wound healing rate at 4 weeks and time to complete wound closure, followed for up to 6 months.

“A total of 500 patients receiving the cell suspension therapy combined with standard surgical procedures will be enrolled from multiple hospitals across China.”

NIH , verbatim from source
Published by NIH on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.

What changed

A new clinical trial registration for basement membrane regeneration in wound repair has been added to ClinicalTrials.gov. The study is a prospective, multicenter, real-world observational study that will enroll 1,000 patients across multiple hospitals in China, with 500 receiving the cell suspension therapy and 500 in the control group receiving standard surgical procedures alone.

Healthcare providers, clinical researchers, and wound care specialists should monitor this trial's outcomes, as positive results could influence treatment protocols for wound healing. The study's 6-month follow-up period and specific outcome measures including wound healing rate at 4 weeks and time to complete wound closure will provide data on the effectiveness and safety of this autologous cell-based approach.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← ClinicalTrials.gov Studies

Basement Membrane Regeneration for Wound Repair

Observational NCT07551284 Kind: OBSERVATIONAL Apr 24, 2026

Abstract

This study is a prospective, multicenter, real-world observational study. It aims to evaluate the effectiveness and safety of autologous basement membrane regeneration technology (epidermal basal cell suspension prepared using a cell sorting system) for wound repair in patients undergoing skin grafting, flap surgery, or primary suture. A total of 500 patients receiving the cell suspension therapy combined with standard surgical procedures will be enrolled from multiple hospitals across China. Their outcomes will be compared with 500 matched patients receiving standard surgical procedures alone (e.g., skin grafting, flap surgery, or suture without cell suspension). The primary outcomes include complete wound healing rate at 4 weeks (for grafted wounds) and time to complete wound closure (for sutured or flap-repaired wounds). Secondary outcomes include wound area reduction rate, recurrence rate, scar assessment (Vancouver Scar Scale), pain score (ASA), sweat function test, basement membrane integrity (histopathology with collagen IV and VII staining if clinically indicated), and safety. Patients will be followed for up to 6 months.

Conditions: Wound Healing

Interventions: Autologous Epidermal Basal Cell Suspension

View original document →

Get daily alerts for ClinicalTrials.gov Studies

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from NIH.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
NIH
Published
April 24th, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical trial registration Wound repair research Cell therapy evaluation
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Topics
Public Health

Get alerts for this source

We'll email you when ClinicalTrials.gov Studies publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!